The reiteration of an Overweight rating and maintenance of a $114 price target by a reputable analyst firm like Cantor Fitzgerald could instill confidence among investors and potentially lead to a positive short-term impact on Ultragenyx Pharmaceutical's stock price. Analyst ratings and price targets are closely watched by investors as indicators of a stock's future performance.